På denne side bringer DANSK BIOTEK nyheder fra medlemmerne, som på denne måde får mulighed for at blive ekstra eksponeret.

Vi modtager derfor gerne pressemeddelelser og andre nyheder. Send dem til Dorte Dannemann, hjælp af denne formular.

11 Oct 2010

Lundbeck enters into license agreement with Kyowa Hakko Kirin

H. Lundbeck has signed an agreement with Kyowa Hakko Kirin Co., Ltd. providing Lundbeck with exclusive rights to develop and commercialise the adenosine A2a antagonist KW-6356. Lundbeck will also have the right to further select compounds as either back-up or additional indication compounds. Adenosine A2a antagonists have potential applications in a wide range of therapeutic indications, including Parkinson’s disease. Kyowa Hakko Kirin will retain rights to develop and commercialise the compounds in Japan and the Asian region.

If you can't find it here or have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or 28895854

Copyright 2010 Danskbiotek. All rights reserved.